Exploring the prognosis of rictor(+) in high-risk population: lasso regression for enhancing overall survival in primary gastric adenocarcinoma

探讨 Rictor(+) 在高危人群中的预后:Lasso 回归分析在提高原发性胃腺癌患者总生存率方面的应用

阅读:1

Abstract

OBJECTIVE: To identify optimal methods for predicting survival in high-risk Rictor (+) gastric adenocarcinoma patients post-gastrectomy. METHODS: 676 patients diagnosed with gastric adenocarcinoma and Rictor (+) status who underwent radical gastrectomy at three medical centers between May 2005 and December 2022 were analyzed. The prognostic variables linked with overall survival were meticulously evaluated through the sophisticated lenses of multiple Cox Proportional Hazards regression and Lasso regression analyses. RESULTS: The Cox regression model included gender, age, positive lymph node count, and biomarkers (HER2, P27, P53), achieving a C-index of 0.759 (95% CI: 0.723–0.796). The Lasso regression model incorporated age, pT stage, lymph node involvement, neural invasion, and tumor diameter, demonstrating superior predictive accuracy (C-index: 0.797; 95% CI: 0.729–0.865). Both models outperformed the AJCC 8th edition TNM staging system (C-index: 0.69, 95% CI: 0.659–0.722). Calibration curves revealed strong concordance between predicted and observed survival outcomes. Decision curve analysis affirmed clinical utility, while risk reclassification metrics showed significant improvements over AJCC staging: net reclassification improvement (NRI) reached 0.218 (P < 0.01) and 0.178 (P = 0.033) in training and validation cohorts, respectively, with integrated discrimination improvement (IDI) values of 0.085 (P < 0.01) and 0.059 (P = 0.028). CONCLUSION: Our findings underscore the enhanced predictive accuracy of Lasso regression over the traditional Cox regression model for identifying high-risk gastric adenocarcinoma patients with Rictor (+) status post-gastrectomy. This novel analytical approach may represent a pivotal advance in the stratification of patients at elevated risk, potentially guiding more precise preventive and therapeutic strategies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12957-025-04043-2.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。